Cholesterol after menopause often rises even when nothing about your diet, weight or exercise has changed. LDL cholesterol climbs through the transition, and in UK guidance the decision about a statin turns on your ten-year cardiovascular risk, not on one lab number.
What cholesterol actually is:
Cholesterol is a waxy fat that every cell membrane needs and your liver makes most of. It travels in particles called lipoproteins, because fat and water do not mix. LDL carries cholesterol to your tissues and, when there is more than the tissues need, into the walls of your arteries. HDL carries the surplus back to the liver. Non-HDL is simply total cholesterol minus HDL: everything in your blood that can end up in plaque, which is why UK guidance sets its treatment targets on it.
Triglycerides are a different fat, carried in the same particles. Most of Europe and the UK report lipid results in millimoles per litre (mmol/L); the United States reports milligrams per decilitre (mg/dL). A full lipid profile means total cholesterol, HDL, non-HDL and triglycerides together. NICE NG238, the UK guideline on cardiovascular risk and lipid modification, says both total cholesterol and HDL should be measured so that risk is estimated properly, and that a fasting sample is not required.
Why LDL rises after menopause:
Oestrogen is not only a reproductive hormone. It helps the liver clear LDL from the blood, and when oestrogen falls, that clearance slows. The result is a rise in LDL and often in triglycerides that has little to do with how carefully you eat.
The 2026 review by El Khoudary and colleagues in Climacteric describes perimenopause as a period when changes in lipid profile, insulin sensitivity, body composition and vascular function accelerate "beyond those expected from aging alone". In other words, the rise is a feature of the transition itself, not just of getting older. The Study of Women's Health Across the Nation (SWAN), which followed midlife women in five US communities for 13 years, found median triglyceride levels rose by 16% over follow-up (Chang et al., Journal of Clinical Endocrinology and Metabolism, 2016).
This matters clinically. If a woman who has always had a normal lipid profile is told her cholesterol is raised and told to eat less fat, she hears advice that assumes a cause she does not have. The most useful conversation is about what changed, what her absolute risk is now, and what, if anything, needs treating.
What your lipid numbers mean:
Laboratories print a reference range beside each result, and that range is easy to misread. It describes the middle of a population, not a target for you. A result inside the range is not automatically fine, and one outside it is not automatically a problem. What matters is the pattern and your risk.
| Measure | What it tells you | How UK guidance uses it |
|---|---|---|
| Total cholesterol | All the cholesterol in your blood, including the protective HDL | Measured with HDL to estimate risk; above 9.0 mmol/L needs specialist assessment |
| LDL cholesterol | The cholesterol that settles into artery walls | Not a target on its own; the 40% reduction aim applies to non-HDL |
| HDL cholesterol | Returns cholesterol to the liver; higher is usually better | Part of the risk calculation; a low level counts as a risk factor |
| Non-HDL cholesterol | Total minus HDL: all the cholesterol that can cause harm | The main target in UK guidance; above 7.5 mmol/L needs specialist advice |
| Triglycerides | Fat carried in the same particles; rises most at menopause | Very high values (above 4.5 mmol/L, or 9 in some labs) can stop a lab reporting a calculated LDL |
Read the table downwards, not one row at a time. A high total cholesterol with a high HDL and low triglycerides describes a different person from the same total with a low HDL and high triglycerides. Both can have the same LDL; only one is likely to be reassured.
The number that decides a statin is your ten-year risk:
NICE NG238 does not offer statins on the strength of an LDL value alone. It says to use the QRISK3 calculator, which estimates the chance of a heart attack or stroke in the next ten years for people aged 25 to 84 who have no existing cardiovascular disease. It then offers atorvastatin 20 mg to anyone whose ten-year risk is 10% or more.
There are three qualifications that often get lost. First, a risk below 10% does not rule out a statin. The guideline says not to rule it out just because the score is under 10% if you have an informed preference for taking one, or if your clinician thinks the score underestimates your risk. Second, a lifetime risk tool such as QRISK3-lifetime can be used to inform the discussion, especially for people under 40 or with a score under 10%, though it is not used to decide treatment. Third, the aim once a statin is started is a reduction in non-HDL cholesterol of more than 40%.
For people who already have cardiovascular disease, the targets are different and tighter: an LDL of 2.0 mmol/L or less, or a non-HDL of 2.6 mmol/L or less.
Does HRT raise or lower cholesterol?
The answer depends on the route, and the route is the part that rarely gets explained. Oestrogen taken by mouth passes through the liver before it reaches the rest of the body. That first pass lowers LDL somewhat and raises triglycerides. Transdermal oestrogen, given as a patch or gel, avoids it, so it generally has little effect on triglycerides.
Neither effect makes HRT a cholesterol treatment. HRT is prescribed for symptoms and for bone protection, and NICE NG23 does not list lipid lowering among its reasons to start. If your lipids rise on HRT, that is worth a review of the route and the dose, not an automatic assumption that the HRT is at fault. Perimenopausal lipids rise with or without treatment.
What actually moves LDL:
Diet and movement change LDL by a smaller amount than most people expect, and by more than most people achieve. The levers, roughly in order of size:
- Cut saturated fat. Butter, cheese, fatty meat, palm oil and pastries are the main sources in most diets; replacing them with olive oil, nuts, seeds and oily fish is the single biggest dietary change.
- Add soluble fibre. Oats, barley, beans, lentils, psyllium and apples bind cholesterol in the gut. Roughly 5 to 10 g a day is the range that shows an effect.
- Consider plant stanols or sterols, 2 g a day, found in fortified spreads and drinks. They lower LDL modestly and are not a substitute for the other steps.
- Move more. Aim for 150 minutes of moderate activity a week plus two sessions of strength work; the strength work also protects bone and muscle, which matter as much at this stage.
- Watch alcohol and stop smoking. Both affect triglycerides and overall risk directly.
- Ask about your thyroid. An untreated underactive thyroid raises LDL, and NICE lists hypothyroidism among the common secondary causes to exclude before anyone concludes the problem is genetic.
A decline of 10 to 15% from diet alone is a realistic result for someone who changes consistently. That is worth having, and it is also why a scan of the numbers after three months, not three weeks, is the fair test.
Do statins work in women, and what are the side effects?
Statins lower LDL by blocking the enzyme the liver uses to make cholesterol, so the liver pulls more LDL out of the blood. NICE recommends atorvastatin 20 mg as the starting dose for primary prevention, with the dose increased if the target is not met. The evidence behind that recommendation applies to women as well as men.
The side effect people worry about most is muscle pain, and NG238 gives a useful figure. When high-intensity statins are used, about 16% of people report muscle pain, tenderness or weakness, but only around 1 in 12 of those cases is likely to be caused by the statin itself. Severe muscle damage is described as extremely low. If you do get muscle symptoms, the guideline says to measure creatine kinase and to consider a lower dose rather than stopping altogether. Grapefruit juice and some supplements interact with statins, so mention everything you take.
How often to check, and what to ask for:
NICE suggests considering an annual full lipid profile to inform conversations about prevention, and a full profile before starting a statin. A fasting sample is not required. If a result is surprising, the fair move is to repeat it after three months of consistent change, and to check thyroid function at the same time if it has not been checked recently.
At your appointment, four questions do most of the work. What is my ten-year QRISK3 score? What is my non-HDL, not just my total? Has my thyroid been checked? And if I am on HRT, is the route the one that suits my lipids?
What this means in practice:
A cholesterol result after menopause is information, not a verdict. Some women will need a statin and will benefit from it. Many will not, at least not yet. The useful response is to know your absolute risk, know your non-HDL, change the two or three things that measurably move it, and recheck rather than guess. Being told "it is just the menopause" and being told "you need medication" are both incomplete answers; the number in between is the one that decides.
When to see a doctor:
- A total cholesterol above 9.0 mmol/L or a non-HDL above 7.5 mmol/L, which needs specialist assessment.
- A strong family history of early heart disease, or relatives with very high cholesterol, which can mean familial hypercholesterolaemia.
- Chest pain, breathlessness on exertion, or pain in the jaw, neck or arm that comes on with effort.
- New high cholesterol alongside unexplained weight loss, hair thinning, cold intolerance or fatigue, which can point to thyroid disease.
- Cholesterol that keeps rising despite consistent diet and exercise changes for three months.
- Muscle pain, tenderness or weakness that starts after a statin and does not settle.
- Any result that worries you, or a plan you do not understand.